I'm considering a position after earnings. I've learned that cash flow is critical while a biotech is in R&D phase. I looked at a number of reports and best I can tell is that their cash burn rate indicates they will be out of cash within 12-18 months and would need to raise more (causing dilution). Anyone else have a better number? If this is true, I'd look to add after a follow-on offering.
12-18 months of cash for a biotech is gold. Do you have any idea how much different this company will look after data in three months? If data is good then NBS becomes a $600 million company very quickly, and will likely be a multi-billion dollar company within two years. AMR-001 has billion dollar potential and its pipeline has many billions in potential. A successful AMR-001 trial will insinuate to Wall St that NBS has other gems in its pipeline.